Comments
Commented by Nico Popp on September 26th, 2025 | 07:30 CEST
AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry
Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.
Read
Commented by André Will-Laudien on September 26th, 2025 | 07:25 CEST
Shooting down Russian drones and fighter jets? NATO keeps its focus on Rheinmetall, Almonty and Hensoldt!
On the financial markets, Russian provocations involving jet and drone overflights are primarily perceived as a security risk. Such actions increase political instability and often trigger a flight to safe havens such as gold, government bonds, or the US dollar. At the same time, defense stocks and companies in the security sector tend to benefit, as investors anticipate rising defense spending in Europe and within NATO. For the broader equity market, the increased risk often translates into higher volatility and temporary price setbacks. In the long term, such threat scenarios are factored into risk premiums and valuation models, leading to more selective capital allocation in security-related sectors. Here are a few ideas.
Read
Commented by Nico Popp on September 26th, 2025 | 07:20 CEST
One-stop shop – Battery metals from a single source: Umicore, BASF, Power Metallic Mines
Anyone who is often in a rush knows the challenge after work: just a quick trip to the store. In such cases, we usually head to our trusted supermarket, where we can find all the products we need in one place. The same principle applies in mining. Complex products, such as modern high-performance batteries for electric vehicles, require a wide range of metals. Polymetallic deposits are therefore in particularly high demand – they are like the familiar neighborhood supermarket for industrial customers. We explain why Power Metallic Mines has the potential to become a one-stop shop for potential major customers such as Umicore and BASF.
Read
Commented by André Will-Laudien on September 26th, 2025 | 07:15 CEST
BioNxt Solutions – Biotech specialist with significant leverage in mega markets
Modern medicine faces an enormous challenge: More and more people are suffering from so-called diseases of affluence, such as obesity, diabetes, multiple sclerosis, and MASH, the dreaded fatty liver disease. At the same time, there is a growing need for innovative therapies and new dosage forms that make treatments more effective, simpler, and more patient-friendly. This is precisely where BioNxt Solutions comes in, a young biotech company that is addressing several billion-dollar markets with its patented thin-film technology. By enabling the oral administration of important active ingredients such as semaglutide and cladribine, BioNxt is not only opening up new therapeutic avenues but also significantly enhancing the effectiveness of existing drugs. At a time when pharmaceutical giants are investing billions in new solutions, BioNxt could become one of the most exciting future players in the industry.
Read
Commented by Armin Schulz on September 26th, 2025 | 07:10 CEST
Is the turbo kicking in? A look at the strategies of Plug Power, Pure Hydrogen and Ballard Power
The race for the future of industrial energy is entering its decisive phase. While global energy demand continues to grow unabated, high CO₂ prices and strict climate regulations are driving explosive demand for clean solutions. Green hydrogen, in particular, promises to revolutionize energy-intensive sectors such as steel and logistics, opening up a market worth billions. Pioneers with concrete technologies and projects stand to benefit the most from this boom. This dynamic makes companies like Plug Power, Pure Hydrogen, and Ballard Power key players who are now in the spotlight.
Read
Commented by Fabian Lorenz on September 26th, 2025 | 07:05 CEST
Will silver rise to USD 130? First Majestic Silver, Pan American Silver, Silver North shares!
Silver will shine like gold in 2025. After rallying to over USD 40 per ounce, one super bull even believes it could reach USD 130. He points to supply shortages, strong industrial demand, and its undervaluation relative to gold. At the company level, Silver North Resources is generating news flow with exploration programs in the Yukon and initial indications of new high-grade mineralization. Will the stock soon take off? Pan American Silver is strengthening itself through the acquisition of MAG Silver and reporting record results with 5.1 million ounces of silver. In addition, the dividend has been increased. Analysts see buying opportunities. RBC recently raised its price target for the base investment in the silver sector.
Read
Commented by Fabian Lorenz on September 23rd, 2025 | 07:20 CEST
NATO under pressure! Almonty target price rises! RENK not a favorite at Goldman Sachs! DroneShield hits milestone!
Russia is testing NATO! Drones and fighter jets are repeatedly being spotted in European airspace, showing that de-escalation is not happening. NATO must continue to strengthen its defenses. This offers opportunities for investors across the entire value chain of the defense industry. In the raw materials sector, Almonty shares are a top pick. Analysts expect the tungsten producer to see an explosion in profits in the coming years and are raising their price target. Could the US government even step in? DroneShield has reached a milestone thanks to follow-up orders from the US Department of Defense. The drone defense specialist sees itself well-positioned for the future. Goldman Sachs has commented on RENK for the first time, but the analysts have other favorites.
Read
Commented by Nico Popp on September 23rd, 2025 | 07:10 CEST
The AI doctor in your pocket: PanGenomic Health, Bayer, CVS Health
Healthcare costs are a pressing political issue worldwide - in Germany, for example, debates are resurfacing over co-payments and the requirement to see a general practitioner first. This drives more people to self-medicate. The situation is even more extreme in the US: without mandatory insurance and facing extremely high healthcare costs, almost 9% of the population is uninsured, and around 33% is underinsured, leading many citizens to turn to alternative solutions. We examine business models related to increasing personal responsibility in healthcare, with a special focus on a smaller-cap stock.
Read
Commented by Stefan Feulner on September 23rd, 2025 | 07:05 CEST
Strategy, Finexity AG, Coinbase – The future starts now!
The financial world is facing profound change: blockchain, cryptocurrencies, and the tokenization of assets are opening up entirely new perspectives for investors. While digital currencies have long since found their way into portfolios, the real game changer is tokenization. Real estate, infrastructure projects, and even works of art can now be digitally represented in an efficient, transparent, and cost-effective manner. Experts expect the market for tokenized assets to multiply in the coming years and grow into a trillion-dollar market. In addition to well-known players, numerous innovative companies are already working behind the scenes on scalable platforms and trading solutions that have so far received little attention on the stock market. This is precisely where the most exciting opportunities for early investors could arise.
Read
Commented by Nico Popp on September 23rd, 2025 | 07:00 CEST
What MASH could do for your portfolio: BioNxt, Roche, Novo Nordisk
Have you heard of MASH? The acronym stands for metabolic-associated steatohepatitis, which was previously simply called "fatty liver." Medications targeting this disease, which studies suggest affects around 6% of Americans, are being hailed as the next big trend in the biotech market. Overall, one in three overweight individuals is affected. Since many patients initially show no symptoms, MASH is considered particularly insidious. The growing discussion around the condition could turn many at-risk individuals into patients who take medication, which is excellent news for certain companies in the sector. For a small-cap stock, the hype surrounding MASH could even be transformative.
Read